Glenmark pharma manufactures and markets generic formulation products and active

pharmaceutical ingredients (API), both in the domestic and international markets. In the formulation
business, its business spans segments such as Dermatology, Internal Medicine, Paediatrics,
Gynaecology, ENT and Diabetes. Acquiring or merging with auribindo pharma will give a boost to its
product portfolio as aurobindo pharma manufactures and markets products in six major segments
namely antibiotics, anti-retrovirals, cardiovascular products, central nervous system products,
gastroenterologicals, and anti-allergics.
This will not only give itself a wider market to serve but also strengthen itself to compete with
industry leaders.